Table 1.
Baseline characteristics of the study population
| Variable | COPD (n=29) | Controls (n=10) | Significant (P-value) |
|---|---|---|---|
| Age (years) | 60 (53–65) | 30.5 (20.8–52.3) | 0.001* |
| Sex | |||
| Male/female; n (%) | 21 (72.4)/8 (27.6) | 5 (50)/5 (50) | 0.250 |
| Smoking history | |||
| Current/former/passive; n (%) | 16 (55.2)/5 (17.2)/8 (27.6) | 5 (50)/0 (0)/5 (50) | 0.290 |
| Pack/year index | 57.5 (35–75) | 30 (24–35) | 0.047* |
| Spirometry | |||
| FEV1/FVC | 55 (46–60) | 82 (77.8–88.3) | 0.001* |
| FEV1 (L) | 1.4 (0.8–1.75) | 2.75 (2.5–3.1) | 0.002* |
| FEV1 % predicted | 54 (35–65) | 90 (72.5–106) | 0.008* |
| GOLD stage | |||
| GOLD B/GOLD D | 12 (41.4)/17 (58.6) | – | NA |
Note:
*
P≤0.05 is considered significant. Data expressed as median (IQR=25th–75th percentile) unless otherwise stated. “–” not relevant.
Abbreviations: FEV1, forced expiratory volume 1; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; IQR, interquartile range; NA, not assessed.